All three tenses have at least two readings, so the archetype blend applies as printed.
Of the nine metrics, 7 read as filed from the record and 2 are SI estimates, each with its reasoning, its confidence and what would change it on its card.
What did they actually do?
Has it survived what it has been through?
3 warning events since 2017; the latest 2025-04-30.
From the record
Trinity Biotech plc's filings since 2017 show 3 warning events: a late-report notice (Form NT 10-K or NT 10-Q, 3 times, the latest 2025-04-30) (its current reports).
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What has it actually done, year after year?
-5.3% a year over 10 filed years; profitable in 1 of 10.
From the record
Trinity Biotech plc's 10 filed years say what it did: revenue went from $100 million in fiscal 2015 to $62 million in fiscal 2024, down 5.3% a year; it rose in 2 of 9 years; the deepest fall was 44% from fiscal 2020 to fiscal 2023; net income was positive in 1 of 10 of those years (its annual reports).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
How has it treated the people who own it?
SI estimate 2.5/10, confidence 35 of 100 (one part).
SI estimate Inferred, not read as filed
From the record
SI estimate, not a filed reading: Trinity Biotech plc's shareholder treatment is put at 2.5 of 10 with a confidence of 35 of 100, because read from one part only, the share count over the years, which ranks in the bottom 25% of 18 in its family; fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income. A filing that carries the missing parts replaces this estimate with the filed reading.
What are they doing right now?
Is it financially healthy right now?
Leverage 134%: owes 134¢ per asset dollar.
From the record
Return on equity: in the fiscal year ended 2024-12-31, Trinity Biotech plc's shareholders' equity was below zero, so the profit on it is not read, and gross profitability: its products earned about 21 cents per dollar of everything the company owns. Leverage: it owed about 134 cents per dollar of assets, and net share issuance: its share count grew 134.6% over the year (the filed statements).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
How strong is its position in its industry?
bottom 45% of 17 in its family; net margin -50.7%.
From the record
Trinity Biotech plc's standing among 17 graded names in its industry family: revenue of $62 million in fiscal 2024 ranks in the top 38% by size; a net margin of -50.7% ranks in the top 50%; revenue growth of -8.8% a year over the last 3 filed years ranks in the bottom 22% (its annual reports).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What are the people in charge doing?
SI estimate 4.6/10, confidence 20 of 100 (family median).
SI estimate Inferred, not read as filed
From the record
SI estimate, not a filed reading: Trinity Biotech plc's leadership is put at 4.6 of 10 with a confidence of 20 of 100, because it files no Form 8-K (a foreign issuer reports on Form 6-K), so officer and director changes cannot be read there; the record of its people begins on 2026-04-03 (a listing, a merger or a first filing under the rules) and most of the people in charge have filed since then, so the record shows a floor of 7 months and cannot see past it; a floor under five years is not read as years in charge, so the desk assumes the typical reading of its industry family, the median of 15 members with one. Its next annual report on file with the inputs replaces this estimate with the filed reading.
What are they set up to do next?
How much room does it have to grow?
bottom 45% of 16 in its family for room to expand.
From the record
Trinity Biotech plc's room to grow, from the newest filed statements (fiscal 2024): cash of $5 million against no long-term debt tagged leaves 5% of its assets as net cash, top 42% of its family; cash from operations less capital spending is -7.5% of revenue (top 41%); a gross margin of 34.8% (bottom 29%); research spending of 7.4% of revenue (bottom 34%) (its annual report).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What could actually drive growth from here?
top 50% of 17 in its family for growth drivers.
From the record
Trinity Biotech plc's growth drivers, from the filed years to fiscal 2024: revenue grew -8.8% a year over the last three filed years against -5.3% over all 10, slowing (bottom 30% of its family); the newest year grew 8.3% (top 26%); research spending grew 0.3% a year (top 32%); capital spending grew -39.3% a year (bottom 30%) (its annual reports). Trinity Biotech plc tags no split of its revenue by line in the annual report on file, so growth by line cannot be read here; research and capital spending are on the trend.
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
Did its newest year beat what its own record pointed to?
bottom 47% of 16 in its family for expectations against reality.
From the record
Trinity Biotech plc's newest year against its own record: revenue of $62 million in fiscal 2024 came in 29.4% above the $48 million its prior three years' pace pointed to (top 17% of its family); net income of $31 million against a prior three-year average of $27 million (bottom 28%); a net margin of -50.7% against -45.6% before (bottom 28%) (its annual reports).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
The grade is the company against its own industry, from its filings. It is not a view on the share price. How the grade is made